BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9615862)

  • 21. Nascent DNA Proteomics Reveals a Chromatin Remodeler Required for Topoisomerase I Loading at Replication Forks.
    Ribeyre C; Zellweger R; Chauvin M; Bec N; Larroque C; Lopes M; Constantinou A
    Cell Rep; 2016 Apr; 15(2):300-9. PubMed ID: 27050524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A tale of topoisomerases and the knotty genetic material in the backdrop of Plasmodium biology.
    Singh P; Rani K; Gotmare A; Bhattacharyya S
    Biosci Rep; 2022 Jun; 42(6):. PubMed ID: 35699968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Need for DNA topoisomerase activity as a swivel for DNA replication for transcription of ribosomal RNA.
    Brill SJ; DiNardo S; Voelkel-Meiman K; Sternglanz R
    Nature; 1987 Mar 26-Apr 1; 326(6111):414-6. PubMed ID: 2436053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Altered topoisomerase I activity and recombination activating gene expression in a human leukemia cell line resistant to doxorubicin.
    Riou JF; Grondard L; Petitgenet O; Abitbol M; Lavelle F
    Biochem Pharmacol; 1993 Sep; 46(5):851-61. PubMed ID: 8396937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decatenation activity of topoisomerase IV during oriC and pBR322 DNA replication in vitro.
    Peng H; Marians KJ
    Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8571-5. PubMed ID: 8104339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nicking of rat spermatid and spermatozoa DNA: possible involvement of DNA topoisomerase II.
    McPherson SM; Longo FJ
    Dev Biol; 1993 Jul; 158(1):122-30. PubMed ID: 8392468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human DNA topoisomerase I: relaxation, roles, and damage control.
    Leppard JB; Champoux JJ
    Chromosoma; 2005 Jul; 114(2):75-85. PubMed ID: 15830206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early effects of topoisomerase I inhibition on RNA polymerase II along transcribed genes in human cells.
    Khobta A; Ferri F; Lotito L; Montecucco A; Rossi R; Capranico G
    J Mol Biol; 2006 Mar; 357(1):127-38. PubMed ID: 16427078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a unique domain essential for Escherichia coli DNA topoisomerase III-catalysed decatenation of replication intermediates.
    Li Z; Mondragón A; Hiasa H; Marians KJ; DiGate RJ
    Mol Microbiol; 2000 Feb; 35(4):888-95. PubMed ID: 10692165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topoisomerase II, not topoisomerase I, is the proficient relaxase of nucleosomal DNA.
    Salceda J; Fernández X; Roca J
    EMBO J; 2006 Jun; 25(11):2575-83. PubMed ID: 16710299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA topoisomerases in mtDNA maintenance and ageing.
    Sobek S; Boege F
    Exp Gerontol; 2014 Aug; 56():135-41. PubMed ID: 24440386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts.
    Thielmann HW; Popanda O; Gersbach H; Gilberg F
    Carcinogenesis; 1993 Nov; 14(11):2341-51. PubMed ID: 8242865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nuclear matrix attachment regions and topoisomerase II binding and reaction sites in the vicinity of a chicken DNA replication origin.
    Razin SV; Vassetzky YS; Hancock R
    Biochem Biophys Res Commun; 1991 May; 177(1):265-70. PubMed ID: 1645958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SFV topoisomerase: sequence specificity in a genetically mapped interval.
    Palaniyar N; Fisher C; Parks R; Evans DH
    Virology; 1996 Jul; 221(2):351-4. PubMed ID: 8661446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drugs acting on DNA topoisomerases: recent advances and future perspectives.
    Gatto B; Capranico G; Palumbo M
    Curr Pharm Des; 1999 Mar; 5(3):195-215. PubMed ID: 10066890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential control of transcription-induced and overall DNA supercoiling by eukaryotic topoisomerases in vitro.
    Wang Z; Dröge P
    EMBO J; 1996 Feb; 15(3):581-9. PubMed ID: 8599941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Site-specific in vivo cleavages by DNA topoisomerase I in the regulatory regions of the 35 S rRNA in Saccharomyces cerevisiae are transcription independent.
    Vogelauer M; Camilloni G
    J Mol Biol; 1999 Oct; 293(1):19-28. PubMed ID: 10512712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication.
    DiNardo S; Voelkel K; Sternglanz R
    Proc Natl Acad Sci U S A; 1984 May; 81(9):2616-20. PubMed ID: 6326134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure of the N-terminal fragment of topoisomerase V reveals a new family of topoisomerases.
    Taneja B; Patel A; Slesarev A; Mondragón A
    EMBO J; 2006 Jan; 25(2):398-408. PubMed ID: 16395333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.